|
Dr. Elmaleh, the scientific founder of FluoroPharma Inc., is an Associate Professor at Harvard Medical School and the Director of Contrast Media Chemistry at the Massachusetts General Hospital. He is an inventor of three drugs that are in use in man or in late stage clinical trials including: The radiopharmaceutical preparation of (2FDG) which has been used in over a million PET imaging procedures, Beta-methyl modified fatty acid (BMIPP) a commercially successful cardiac SPECT agent, and Altropane which has completed Phase III clinical trials. His recent work has included extensive research on imaging compounds to improve the speed and effectiveness of cardiovascular disease diagnosis which constitutes the technology licensed from MGH to FluoroPharma. He is a co-author on over 120 publications and an inventor of over 40 issued and pending patents in a range of disciplines, including molecular imaging and pharmaceuticals. Dr. Elmaleh is a recipient of numerous NIH and DOE awards, and has participated as a reviewer for the National Institute of Health (NIH). He is the Scientific Founder of Biostream (changed name to Molecular Insight Pharmaceuticals) and several other start-ups. He holds a BSc in Physics and Chemistry, and an MS and PhD in Chemistry from the Hebrew University of Jerusalem.
David R. Elmaleh, PhD
Chairman, Director and Chief Scientific Advisor
Dr. Elmaleh, the scientific founder of FluoroPharma Inc., is an Associate Professor at Harvard Medical School and the Director of Contrast Media Chemistry at the Massachu... Read Full Bio
Walter Witoshkin.
| 